All In Biotech

NDA 214324 · United Therap

Tyvaso Dpi

Treprostinil · Inhalation · Prostacycline Vasodilator

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

May 23, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

129

42 Phase 3, 15 recruiting

FAERS reports

17,039

9,139 serious, 1,531 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2025.

Tyvaso DPI is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with Tyvaso establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study with Tyvaso establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) 1.1 Pulmonary Arterial Hypertension Tyvaso DPI is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies with Tyvaso establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). The effects diminish over the minimum recommended dosing interval of 4 hours; treatment timing can be adjusted for planned activities. While there are long-term data on use of treprostinil by other routes of administration, nearly all clinical experience with inhaled treprostinil has been on a background of an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor. The controlled clinical experience with Tyvaso was limited to 12 weeks in duration [see Clinical Studies (14) ] . 1.2 Pulmonary Hypertension Associated with ILD Tyvaso DPI is indicated for the...

Mechanism: Treprostinil is a prostacyclin analogue. The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 23, 2022 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanLabelLetterReview
5 products under this application
  • TYVASO DPI · TREPROSTINIL 0.08MG/INH · POWDER, INHALATION · Prescription
  • TYVASO DPI · TREPROSTINIL 0.048MG/INH · POWDER, INHALATION · Prescription
  • TYVASO DPI · TREPROSTINIL 0.016MG/INH · POWDER, INHALATION · Prescription · TE TBD
  • TYVASO DPI · TREPROSTINIL 0.064MG/INH · POWDER, INHALATION · Prescription
  • TYVASO DPI · TREPROSTINIL 0.032MG/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil" as an intervention, any sponsor and status, largest first.

All 129 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • cough3,755
  • dyspnoea3,545
  • headache3,034
  • diarrhoea2,400
  • dizziness1,892
  • fatigue1,876
  • nausea1,861
  • oxygen saturation decreased1,205
  • hypotension1,102
  • vomiting905
  • dyspnoea exertional898
  • throat irritation822

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20063
20071
20082
20098
201013
201122
201240
201342
201471
2015146
201690
2017103
2018101
2019456
2020481
2021624
20221,250
20233,218
20243,476
20254,083
20262,808

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Tyvaso Dpi (Treprostinil)

2024 spending

$729M

Beneficiaries

4,385

30,325 claims

Per beneficiary

$166,192

$200.41 per unit

View as table
YearSpending
2020$0
2021$0
2022$78,215,743
2023$436,921,533
2024$728,752,455

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 116 on PubMed

Sponsor: United Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.